COLUMBIA BANKING SYSTEM, INC. REPORTS FOURTH QUARTER 2025 RESULTS

$215 million $243 million $0.72 $0.82 Net income Operating net Earnings per common Operating earnings income(1) share – per diluted common share – diluted(1) CEO Commentary “Our fourth quarter performance marked a strong end to a tremendous year for Columbia, reflecting continued momentum across our businesses and our commitment to consistent, repeatable results,” said Clint

HONEYWELL ANNOUNCES CFO, BUSINESS UNIT LEADERS FOR HONEYWELL AEROSPACE

— Josh Jepsen will join Honeywell Aerospace as CFO; Bob Buddecke, Dave Marinick and Rich DeGraff to lead business units — These leaders will report to President and CEO Jim Currier, forming the core Honeywell Aerospace leadership team — Spin-off of Honeywell Aerospace, which will be one of the largest publicly listed pure-play aerospace and

Lofta and Accomplish Health to Collaborate in Expanding Access to Medical Weight Loss for Millions of Sleep Apnea Patients

Lofta, a leading provider of direct-to-consumer sleep apnea care, today announced a strategic alliance with Accomplish Health, a leading virtual obesity and metabolic health platform. The collaboration expands access to comprehensive, expert-led medical weight loss services for millions of Americans living with sleep apnea who also struggle with obesity. Sleep apnea affects an estimated 30

General Purpose Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about January 23, 2026

MILLBROOK, NY / ACCESS Newswire / January 22, 2026 / General Purpose Acquisition Corp. (the "Company") announced today that holders of the units sold in the Company’s initial public offering of units completed on December 4, 2025 (the "Offering") may elect to separately trade the Class A ordinary shares and redeemable warrants included in the

Bank First Announces Net Income for the Fourth Quarter of 2025

— Net income of $18.4 million and $71.5 million for the three months and year ended December 31, 2025, respectively — Earnings per common share of $1.87 and $7.23 for the three months and year ended December 31, 2025, respectively — Annualized return on average assets of 1.65% and 1.62% for the three months and

Superior Energy Services Announces Pricing of $175 Million Senior Secured Notes Offering

HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) — Superior Energy Services, Inc. (“Superior”) announced today that its wholly-owned subsidiary SESI, L.L.C. (“SESI”) has priced the previously announced offering (the “Offering”) of $175 million aggregate principal amount of its 7.875% Senior Secured Notes due 2030 (the “New Notes”). The New Notes are being offered under the indenture

BitFuFu Presenting at the 3rd Annual DealFlow Discovery Conference

(NASDAQ:FUFU), SINGAPORE, Jan. 22, 2026 (GLOBE NEWSWIRE) — BitFuFu Inc. (“BitFuFu” or the “Company”) (NASDAQ: FUFU), a world-leading Bitcoin miner and mining services innovator, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. Charley Brady, Vice President of Investor Relations, will deliver a company presentation and be available

Amlan(R) International Announces Promotion of Dr. Robin Jarquin to Vice President of Sales – Latin America

(NYSE:ODC), CHICAGO, Jan. 22, 2026 (GLOBE NEWSWIRE) — Amlan(R) International, the animal health business of Oil-Dri(R) Corporation of America (NYSE: ODC), is pleased to announce the promotion of Dr. Robin Jarquin to Vice President of Sales, Latin America. In this expanded leadership role, Dr. Jarquin will leverage his deep industry experience and strong regional expertise

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

(NASDAQ:ARQT), Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing

Scroll to Top